Métastases fœtales et placentaires de mélanome : à propos d’un cas

D. Canu(Hôpital Saint-André), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux)

Annales de Dermatologie et de Vénéréologie

November 19, 2019

10.1016/j.annder.2019.09.504

Cited by 1

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

|New England Journal of Medicine|2014|5.3k

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

|New England Journal of Medicine|2014|2k

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

|New England Journal of Medicine|2017|1.5k

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

|The Lancet Oncology|2018|1k

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

|The Lancet Oncology|2016|1k